Novel Technologies in Diabetes Mellitus Therapy
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (15 August 2022) | Viewed by 5332
Special Issue Editor
Interests: the role of caveoles in the insulin and IGF1 signal; new technologies in the treatment of diabetes mellitus; role of bariatric surgery in the regulation of metabolism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The first use of insulin on 11 January 1921 completely changed the life expectancy of patients with Type 1 Diabetes, which has since become a chronic disease. For many years, however, insulin therapy has been based essentially on clinical criteria. In fact, measuring glycemia was difficult and impossible to do at home. In the 1930s and 1940s, glycosuria became the main index to manage insulin therapy. The use of portable glucometers made the self-monitoring of blood glucose the standard of care, which improved patient quality of life. Now, the use of sensors to determine interstitial glucose represents the last frontier. Along with the development of systems for determining blood glucose, there has been also a notable advance in insulin delivery devices from syringes to pens and insulin pumps.
In 2020, for the first time, the ADA standard of diabetes care included the chapter “Diabetes and Technology.” In the last 20 years, there have been great advances in this field. On the one hand, the number, reliability, and spread of sensors to measure interstitial glycemia greatly increased. On the other hand, the insulin pump evolved toward the closed loop hybrid system. Finally, the high connectivity between the players implied in diabetes management (patients, caregivers, medical and nursing staff) have further expanded and complicated disease management. In this Special Issue of Life, all these aspects will be addressed.
Dr. Davide Maggi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes mellitus therapy
- diabetes and technology
- diabetes and COVID‐19
- diabetes management
- measurement of glycemia
- islets of Langerhans
- insulin delivery
